Watchlist

Watchlist
Albireo Pharma, Inc. (ALBO)
Albireo Pharma, Inc. (ALBO)
Biotech Forum: The Week Ahead
It has always seemed that a fear of judgment is the mark of guilt and the burden of insecurity. Criss Jami, Killosophy Markets plunged Friday in reaction to escalating trade tensions between the U.S. and China. The major indices ended up again in the red last week. The…
Albireo Pharma (ALBO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more …
Albireo Pharma's (ALBO) CEO Ron Cooper on Q4 2017 Results - Earnings Call Transcript
Albireo Pharma, Inc. (ALBO) Q4 2017 Results Earnings Conference Call March 15, 2018 08:30 AM ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Paresh Soni - Chief Medical Officer Analysts Liana Moussatos - Wedbush Securities K…
Daily Insider Ratings Round Up 1/25/18: OPK, ALBO, BMRA, ICBK, PGLC
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi…
Albireo to receive more than $55M on elobixibat approval in Japan
Albireo Pharma (NASDAQ: ALBO ) announces that JapansMinistry of Health, Labor and Welfare has approved the new drug application for IBAT inhibitor elobixibat for the treatment of chronic constipation inJapan. More news on: Albireo Pharma, Inc., Healthcare …
Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea…
Albireo Pharma: Updates To Thesis
Shares of Albireo Pharma ( ALBO ) have risen by close to 20% since I noted that this big pharma spinoff was fully funded with several catalysts lined up. ALBO data by YCharts Keys to the original bullish thesis included the following: Lead clinical candidate A4250, a selective inhibi…
Albireo Pharma (ALBO) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more …
Planned equity offering roundup - healthcare
Recent SEC filings for planned equity offerings: More news on: Bio-Path Holdings, Inc., Albireo Pharma, Inc., Mateon Therapeutics, Inc., Healthcare stocks news, Read more …
Albireo Pharma (ALBO) Updates On Rare Cholestatic Diseases In Children (PFIC & Pruritus, IBAT Inhibition) - Slideshow
The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more …
Albireo Pharma, Inc. (ALBO)